Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders

ABSTRACT

Disclosed are certain cocaine analogs useful for imaging of cocaine receptors and dopamine receptors. Also disclosed are analogs useful for imaging diagnostics for Parkinson&#39;s disease.

STATEMENT OF FEDERALLY SPONSORED RESEARCH

This invention was supported by NIH Grant Numbers DA06303 and DA00499,and the government has certain rights in this invention.

BACKGROUND OF THE INVENTION

The invention relates to substituted nortropanes and their use to image:a) dopamine-transporter-containing neurons, particularly in connectionwith diagnosis and study of certain neurodegenerative disorders; and b)cocaine receptors.

There is a need for diagnostic agents and markers of neurogenerativedisorders such as Parkinson's disease. For example, exclusion at anearly stage of Parkinson's disease as the cause of symptoms may beuseful information in diagnosing other conditions. Moreover, earlydiagnosis of Parkinson's disease can facilitate the introduction ofputative prophylactic drug therapy (e.g., deprenyl) prior to the onsetof more severe symptoms. See, Kaufman and Madras (1991) Synapse 9:43-49.Detection of nerve cell depletion in the presymptomatic phase in ananimal model of Parkinson's disease would also be useful, e.g., whenusing the model to evaluate therapies for Parkinson's disease. See,Hantraye et al. (1992) Neuro Reports 3:265-268; and Hahtraye et al.(1992) Soc. Neurosci. Abstra. 18:935.

There is a particular need for diagnostic agents and markers ofneurogenerative disorders that selectively target a dopaminetransporting protein (the dopamine transporter) in preference to anotherprotein known as the serotonin transporter. In normal brain tissue, thedopamine:serotonin transporter density ratio is approximately 10:1. Incertain neurodegenerative disorders, such as Parkinson's disease, nervecells that produce dopamine (and on which the dopamine transporter islocated) undergo severe depletion, while serotonin nerve cells are lessaffected. The dopamine:serotonin transporter ratio can fall to 50% inParkinson's disease.

Various substances (particularly cocaine and cocaine congeners) arepotent inhibitors of dopamine transport in the striatum of the brainbecause they bind to the dopamine transporter. The more strongly thesesubstances block dopamine transport, the more strongly they bind tosites on the dopamine transporter which have been labeled by [³H]cocaine or by a compound known as [³ H] CFT (also known as [³ H]WIN35,428).¹ See, Madras et al., (1989) J. Pharmacol. Exp. Ther.251:131-141; and Madras et al. (1989) Mol. Pharmacol. 36:518-524.

CFT (WIN 35,428) and similar substances exhibit markedly decreasedbinding in the Parkinson's diseased brain. See, Madras et al. Soc.Neurosci. Abst. 16:14, 1990; and Kaufman and Madras (1991) Synapse9:43-49. The hope that these compounds might be Parkinson's markers isfurther supported by the parallel between loss of binding and loss ofdopamine in the diseased brain (Madras et al. Catechol. Symp. 193,1992).

Dopamine transporter-binding compounds that have been studied includeN-allyl-2 carboxymethyl-3β-fluorophenyltropane. See, Madras et al.(1990) Pharmacology, Biochemistry & Behavior 35:949-953; and Milius etal. (1991) J. Med. Chem. 34:1728-1731.

Goodman et al. report (1992) J. Nuclear Med. 33:890) the synthesis of2-β-carbomethoxy-3-β-(4-chlorophenyl)-8-(¹²³ I-iodopropene-2yl)nortropane. The selectivity of this analog for the dopamine over theserotonin transporter is not discussed.

CFT or WIN 35,428 is approximately 15 times more selective for thedopamine over the serotonin transporter. The 4-chloro analog is 4-foldselective. See Carroll et al., J. Med. Chem. 35:969 (1992); and Meltzeret al., J. Med. Chem. 36:855-862 (1993).

SUMMARY OF THE INVENTION

We have discovered that fluorination of the phenyl substituent ofN-haloallyl phenyl nortropanes yields compounds that are unusuallyeffective for several purposes. The 3E and 3Z isomers of2-β-carbomethoxy-3-β-(4-fluorophenyl)-8-(3-I-iodopropen-2-yl) nortropaneare particularly preferred. We have designated this preferred compoundIodoaltropane or IACFT. Most preferably, the compounds according to theinvention are labeled with radionuclides of the halogen series, such as¹²³ I or ¹²⁵ I.

The special properties of the claimed compounds are best understood withthe following background. Cocaine recognition sites are localized on thedopamine transporter, which itself is localized on dopamine nerveterminals. Drugs that bind to these sites therefore have potential useswhich include: (i) imaging probes for neurodegenerative disorders; and(ii) imaging probes for dopamine transporter/cocaine binding sites.

Because of the unique anatomical location of the cocaine recognitionsites, a high affinity probe for imaging of these sites in vivo in thebrain can be carried out using PET or SPECT imaging. Such imaging isuseful for diagnosing or monitoring Parkinson's disease, a neurologicaldisorder characterized by the degeneration of dopamine nerve terminalsor by aging.

Accordingly, one aspect of the invention features a compound of formula:##STR1##

wherein the following condition is imposed on that formula:

R is --CH₃, --CH₂ CH₃ (α configuration; β configuration or both),--CH(CH₃)₂, --(CH₂)_(n) CH₃, --(CH₂)_(n) C₆ H₄ X, --C₆ H₄ X, --C₆ H₅,--OCH₃, --OCH₃ CH₂, --OCH(CH₃)₂, --OC₆ H₅, --OC₆ H₄ X, --O(CH₂)_(n) C₆H₄ X, or --O(CH₂)_(n) CH₃ ; wherein X is --Br, --Cl, --I , --F, --OH,--OCH₃, --CF₃, --NO₂ --NH₂, --CN, --NHCOCH₃, --N(CH₃)₂, --(CH₂)_(n) CH₃,CHOCH₃, or --C(CH₃)₃ and n is between 0 and 6 inclusive

A second aspect of the invention features the same formula, except thatthe substituent on the N-allyl group can generally be any halogen,preferably --I or --F.

In a third aspect, the invention features a method of detectingparkinsonism in a human patient, involving administering to the patienta detectably labelled compound of the invention and detecting itsbinding to CNS tissue, e.g., by quantifying dopamine terminals with thatcompound (e.g., using positron emission tomography (PET) orsingle-photon emission computed tomography (SPECT)).

In a fourth aspect, the compound is used to monitor cocaine bindingsites of the CNS (e.g. to determine site occupancy by potential cocainetherapeutics).

Such compounds also may be useful in treatment of neurodegenerativedisorders or cocaine abuse.

Preferred compounds according to the invention are characterized asfollows: a) the 2 substituent is in the β position; b) the 3 substituentis in the β position; c) R is --O--CH₃ ; the 8 substituent is either theE isomer or the Z isomer. More preferably the halo substituent on theN-allyl moiety is --I or --Br (particularly a radionuclide of --I or--Br); ¹⁸ F provides also a useful label. Most preferably, the compoundis Iodoaltropane:2-β-carbomethoxy-3-β-(4-fluorophenyl)-8-(3E-iodopropen-2-yl) nortropane.

Also in preferred embodiments, the compound contains a radioactive label(particularly a gamma or position emitter such as ¹²³ I, ¹²⁵ I ¹⁸ F or¹¹ C ¹²³ I is particularly preferred) or a ¹⁸ F fluoro label as part ofthe 3-halopropen-2-yl substituent.

Therapeutic compositions according to the invention comprise a compoundas described above formulated in a pharmaceutically acceptable carrier.Such compositions can be used to selectively image cocaine bindingregions of the central nervous system of a human patient byadministering detectably labelled compound to the central nervous systemand detecting the binding of that compound to CNS tissue. Thecompositions can also be used to detect parkinsonism in a human patientby administering detectably labelled compound to the patient anddetecting the binding of the compound to CNS tissue (e.g., by positionemission tomography (PET) or by single-photon emission computedtomography (SPECT)). Such a compound also may be useful in treatment ofneurodegenerative disorders characterized by dopamine deficits orcocaine abuse.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph depicting association of ¹²⁵ I iodoaltropane with thedopamine transporter. The pharmacological specificity of [¹²⁵ I]iodoaltropane labeled sites (primate striatum) and the dopaminetransporter sites (rodent striatum) are closely associated.

FIGS. 2A-2F are photographs depicting the distribution of ¹²⁵ IIodoaltropane in a primate brain, indicating a close match between thatdistribution and the distribution of dopamine.

FIG. 3 is a diagram of the synthesis of Iodoaltropane.

DETAILED DESCRIPTION OF THE DRAWINGS I. Compound Characterization

Target compounds are prepared as the free bases or salts, e.g., thenaphthalene-1,5-disulfonate, tartrate, or hydrochloride salts. Forexample, these compounds are prepared from the corresponding Z or Eiodo-tri-n-butylstannylallyl precursors. See Example 1, below.

Compounds can be radiolabeled at any of a number of positions. Forexample, a radionuclide of the halogen series may be used in thehaloallyl moiety. Alternatively, a radionuclide can be included in the--R moiety defined above. Radiolabeled iodoallyl compounds may beprepared by reacting the iodoallyl Sn precursor (see FIG. 3) with aradioiodide (provided, e.g., as NaI) under oxidative conditions (e.g.,H₂ O₂ or benzoyl peroxide).

Characterization of the compounds is carried out using standard methodsof high field NMR spectra as well as IR, MS and optical rotation.Elemental analysis, TLC and/or HPLC is used as a measure of purity. Apurity of >98% is preferred before biological evaluation of thesecompounds is undertaken.

II. Binding Assays for Candidate Compounds

To evaluate the selectivity of N-haloallyl nortropane derivatives forthe dopamine transporter, compounds are screened in radioreceptor assaysusing both [³ H]CFT and [³ H]citalopram as probes for the dopamine andserotonin receptors, respectively. The relative affinities of a compoundfor either site establishes whether it binds selectively to the dopaminetransporter or non-selectively to the serotonin transporter as well.Assays are carried out as follows.

Competition studies to determine the potency of a compound forinhibiting specifically bound [³ H]CFT in monkey caudate-putamenmembranes are conducted using 0.3-10 nM [³ H]CFT and the primate braintissue preferably caudate-putamen. The methods are described by Madraset al. (1989) Mol. Pharmacol. 36:518-524. Unlabeled (-)-cocaine (30 μM)serves as the baseline drug to detect non-specific binding. Incubationproceeds at 4° C. for 60 min, and the assay is terminated by vacuumfiltration over glass fiber filters (Whatman GF/B). The filters aremonitored for radioactivity by liquid scintillation spectrometry at 50%counting efficiency. All assays are performed in triplicate, and eachexperiment is repeated at least twice using tissue from differentbrains.

To assay binding of the analog to the serotonin transporter, analogs aretested for their ability to compete with labeled [³ H]citalopram, a highaffinity and selective ligand for serotonin transporter sites (D'Amatoet al., J. Pharmacol. Exp. Ther. 242:364-371, 1987). Radioreceptorassays are conducted using tissues prepared as described above. Analogsare incubated with buffer (50 mMTris HCl; 100 mM NaCl), [³ H]citalopram(1 nM), and tissue (1 mg/ml wet tissue weight), incubated 2 h at 4° C.,and the incubation terminated by rapid filtration. Non-specific bindingis monitored with fluoxetine (1 μM).

Using such an approach, the compounds according to the invention may betested for their ability to inhibit the binding of [³ H]CFT to primatecaudate-putamen. Inhibition by (-)-cocaine and CFT may be used asreference points.

III. SPECT or PET IMAGING

Autoradiographic distribution of the compounds are conducted accordingto in vitro techniques (Kaufman et al. (1991) Synapse 9:177-187) or exvivo techniques (Kaufman and Madras (1992) Synapse 12:99-111).

The cocaine analogs described herein provide useful SPECT or PET imagingprobes. Brain imaging has at least two applications: to monitor thedopamine transporter (dopamine nerve terminals) in neurodegenerativedisorders and cocaine abuse; and to evaluate the time course ofaccumulation of a candidate drug therapy in the brain targeting thedopamine transporter, as well as the duration of receptor occupancy.Such compounds may be useful for cocaine abuse or otherneuro-psychiatric disorders.

Cocaine analogs of high affinity are most useful as SPECT (or PET)imaging probes because they display a low level of non-specific binding,and they accumulate in dopamine regions of brain. High affinity analogsare preferable because dopamine may compete effectively with trace dosesof low affinity analogs in vivo. By these standards, Iodoaltropane is ahigh affinity ligand.

SPECT or PET imaging may be carried out using any appropriate apparatus.Imaging is carried out on conscious human subjects using standardimaging (see, e.g., Medicine, Scientific American, Inc., ed. Rubensteinand Federman, 1988; Jaszczak and Coleman, Invest. Radiol. 20:897, 1985;Coleman et al., Invest. Radiol. 21:1, 1986); preferably SPECT imagingemploys gamma-emitting derivatives of the analogs described herein(e.g., analogs labelled with ¹²³ I).

IV. Analytical Considerations

All target compounds are prepared either as free bases or as suitablepharmacologically active salts such as hydrochloride, tartrate,naphthalene-1,5-disulfonate salts or the like. All target compounds arecharacterized and their purity analyzed prior to any biologicalevaluation. High field NMR spectra are measured as well as IR, MS andoptical rotation for all test compounds. Elemental analysis, TLC and/orHPLC are used as a measure of purity. A purity of >98% is requiredbefore any biological evaluation of these compounds is undertaken.

The following specific examples illustrate but does not limit theinvention.

EXAMPLE 1: GENERAL PROCEDURES FOR THE PREPARATION OF IODOALTROPANETributyltinallyl Alcohol

Propargyl alcohol (5.5. mL, 9.4 mmol) was added dropwise to a mixture oftributyltin hydride (35 mL, 13 mmol) and azobis (isobutyronitrile)(AIBN) (1.6 g, 0.97 mmol) at 80° C. The reaction mixture was heated at80° C. for 2 h. The reaction mixture was chromatographed over silica gel(5% EtOAc/hexane) to afford the E-isomer 16.68 g (51%) and the Z-isomer(23%) as a clear oil.

Tributyltinallyl Chloride

Tributyltinallyl alcohol (12.8 g, 3.7 mmol), triphenylphosphine (9.7 g,3.7 mmol) and CCl₄ (100 mL) were combined and heated at reflux for 16 h.Excess CCl₄ was removed and the residue was chromatographed over silicagel (hexane) to afford 10.78 g (80%) of tributyltin allyl chloride as aclear oil.

Methyl-3β-(p-fluorophenyl)-N-tributyltinallyl-1αH-,5βH-nortropane-2β-carboxylate

Methyl-3β-(p-fluorophenyl)-1αH,5αH-nortropane-2β-carboxylate (102 g,0.39 mmol), (see Meltzer et al., J. Med. Chem. 36:855 (1993))tributyltin allyl chloride (143 mg, 0.39 mmol), KF-celite (50%, 226 mg,1.9 mmol) and CH₃ CN (10 mL) were combined and heated at 70° C. for 17h. The reaction mixture was diluted with 40 mL of ether and filteredthrough a celite pad. The filtrate was concentrated to dryness. Theresidue was chromatographed over silica gel (2% Et₃ N/hexane) to afford163 mg (71%) ofmethyl-3β-)p-fluorophenyl)-N-tributyltinallyl-1αH-,5αH-nortropane-2β-carboxylate.

Methyl-3β-(p-fluorophenyl)-N-iodoallyl-1αH-,5αH-nortropane-2β-carboxylate

Methyl-3β-(p-fluorophenyl)-N-tributyltinallyl-1αH-,5αH-nortropane-2β-carboxylate(161 mg, 0.27 mmol) in THF (10 mL) was degassed by bubbling N₂ throughfor 5 min. NIS (61.8 mg, 0.275 mmol) was added and stirred at roomtemperature for 15 min. THF was removed and the residue waschromatographed over silica gel (2% Et₃ N/hexane) to afford 102 mg (87%)ofmethyl-3β(p-fluorophenyl)-N-iodoallyl-1αH-,5αH-nortropane-2β-carboxylateas a white solid: mp 112°-114° C.

Thus, propargyl alcohol was treated with tributyl tin hydride in thepresence of azobis (isobutyronitrile) to obtain, after columnchromatography over silica gel, the separated E and Z isomers of3-tributyltin allyl alcohol. Each of the alcohols was then reacted withtriphenylphosgene and carbon tetrachloride to obtain the requisite E andZ isomers of 3-tributyltin allyl chloride respectively.

Reaction of each of the 3-tributyltin allyl chlorides withmethyl-3β-(p-fluorophenyl)nortropane-2β-carboxylate (see Meltzer et al.,J. Med. Chem. 36:855 (1993) for the synthesis of this compound) in thepresence of KF-celite gave the desiredmethyl-3β-(p-fluorophenyl)-N-(3-tributyltinallyl)-nortropane-2β-carboxylate in 71% yield after columnchromatography. Conversion of this compound to the iodide was effectedwith N-iodosuccinimide (NIS) in THF to obtainmethyl-3β-(p-fluorophenyl)-N-(3-iodo allyl)-nortropane-2β-carboxylate(Iodoaltropane) in 87% yield.

EXAMPLE 2: PREPARATION OF BROMOALTROPANE

The 2-β-carbomethoxy-3-β-(4-fluorophenyl)-8-(3-bromopropen-2-yl) analog("Bromoaltropane") is prepared generally as described above usingN-bromosuccinimide (NBS) in place of NIS.

EXAMPLE 3: FLUORINATION

The fluoroallyl compounds may be prepared by reacting a correspondinghaloallyl Sn compound with Xe₂ F₂, acetylhypofluroide, or F₂.

EXAMPLE 4

Iodoaltropane was compared to CFT as well as to another candidateiodinated dopamine transporter probes known as RTI-55,² using theabove-described radioreceptor 2 binding techniques on monkey striationhomogenate. The results are as follows.

1. Iodoaltropane is more selective for the dopamine transporter andpossesses higher affinity than CFT (Table 1).

2. Iodoaltropane is more selective than RTI-55, which has a highaffinity but low selectivity for the dopamine transporter (Table 1).

3. [¹²⁵ I]Iodoaltropane labels the dopamine transporter in primatestriatum (see FIG. 1).

4. [¹²⁵ ]Iodoaltropane distributes primarily to dopamine-rich brainregions in primate brain (FIGS. 2A-2F) and its binding is characterizedby low levels of nonspecific binding.

                  TABLE 1                                                         ______________________________________                                        Affinity of Iodoaltropane for the dopamine and                                serotonin transporter                                                                 Dopamine trans.                                                                          Serotonin trans.                                                                          Selectivity                                    ______________________________________                                        Iodoaltropane                                                                           6.62 ± 0.78                                                                             182 ± 46 28                                         CFT       12.9 ± 1.10                                                                             160 ± 20 15                                         RTI-55    1.08 ± 0.06                                                                              2.53 ± 0.02                                                                            2                                         Bromoaltropane                                                                          10.8         212         20                                         ______________________________________                                    

What is claimed is:
 1. A compound of formula: ##STR2## wherein thefollowing conditions are imposed on that formula: R is --CH₃, --CH₂ CH₃,--CH(CH₃)₂, --(CH₂)_(n) CH₃, --(CH₂)_(n) C₆ H₄ X, --C₆ H₄ X , --C₆ H₅,--OCH₃, --OCH₃ CH₂, --OCH(CH₃)₂, --OC₆ H₅, --OC₆ H₄ X, --O(CH₂)_(n) C₆H₄ X, or --O(CH₂)_(n) CH₃ ; wherein X is --Br, --Cl, --I, --F, --OH,--OCH₃, --CF₃, --NO₂ --NH₂, --CN, --NHCOCH₃, --N(CH₃)₂, (CH₂)_(n) CH₃,CHOCH₃, or --C(CH₃)₃, and n is between 0 and 6 inclusive.
 2. A compoundof formula: ##STR3## wherein the following conditions are imposed onthat formula: a) R is --CH₃, --CH₂ CH₃, --CH (CH₃)₂, (CH₂)_(n) CH₃,--(CH₂)_(n) C₆ H₄ X, --C₆ H₄ X, --C₆ H₅, --OCH₃, --OCH₃ CH₂,--OCH(CH₃)₂, --OC₆ H₅, --OC₆ H₄ X, --O(CH₂)_(n) C₆ H₄ X, or --O(CH₂)_(n)CH₃ ; wherein X is --Br, --Cl, --I, --F, --OH, --OCH₃, --CF₃, --NO₂--NH₂, --CN, --NHCOCH₃, --N(CH₃)₂, --(CH₂)_(n) CH₃, CHOCH₃, or--C(CH₃)₃, and n is between 0 and 6 inclusive; andb) where --Q is ahalogen.
 3. The compound of claim 1 or claim 2 having formula A or B:##STR4##
 4. The compound of claim 1 or claim 2 having formula C or D:##STR5##
 5. The compound of claim 1 or claim 2 in which R is --O--CH₃.6. The compound of claim 1 having the formula: ##STR6##
 7. The compoundof claim 1 having the formula: ##STR7##
 8. The compound of claim I orclaim 2 in which said compound is2-β-carbomethoxy-3-β-(4-fluorophenyl)-8-(3-iodopropen-2-yl) nortropane.9. The compound of claim 1 or claim 2 in which at least one atom of saidcompound is a radioactive isotopic label.
 10. The compound of claim 9 inwhich said label is a gamma or positron emitter.
 11. The compound ofclaim 10 in which said label is selected from the group consisting of125I, ¹²³ I ¹⁸ F and ¹¹ C.
 12. The compound of claim 10 in which saidlabel is ¹²³ I.
 13. The compound of claim 2 where Q is --Br.
 14. Thecompound of claim 2 having the formula: ##STR8##